Durable responses to immune checkpoint inhibitor-based regimens for metastatic clear cell renal cell carcinoma stratified by IMDC risk groups: A pooled analysis of four randomized phase 3 trials [0.03%]
基于免疫检查点抑制剂的治疗方案对转移性透明细胞肾细胞癌持久应答的IMDC风险分层：四项随机III期临床试验的汇总分析
Albert Jang,Jeffrey Y Zhong,Hamsa L S Kumar et al.
Albert Jang et al.
Background: An immune checkpoint inhibitor (ICI) backbone is a standard of care for frontline metastatic clear cell renal cell carcinoma, involving either ICI doublet or tyrosine kinase inhibitor (TKI) with ICI. These pha...
Albert Jang,Charbel S Hobeika,Shilpa Gupta
Albert Jang
Papillary renal cell carcinoma (pRCC) comprises 15-20% of all patients with renal cell carcinoma (RCC). Although in the localized setting where pRCC appears to have better outcomes than clear cell RCC (ccRCC), patients with metastatic pRCC ...
Liquid biopsy for Renal Cell Carcinoma: A comprehensive review of techniques, applications, and future prospects [0.03%]
液体活检在肾细胞癌中的应用：技术、应用及未来展望的全面综述
Chinmay Jani,Nour Abdallah,Alan Tan et al.
Chinmay Jani et al.
Liquid biopsy techniques have developed rapidly in recent years and demonstrated success in cancer detection, disease characterization, and ongoing disease monitoring. These components, including circulating tumor cells (CTCs), circulating ...
Post-Metastasectomy Adjuvant Therapy in Patients with Renal Cell Carcinoma: A Systematic Review [0.03%]
肾细胞癌术后转移灶切除术的辅助治疗：系统性回顾
Steven Monda,Primo N Lara,Shuchi Gulati
Steven Monda
Background: Pembrolizumab is established as adjuvant therapy for patients with high-risk clear cell renal cell carcinoma (ccRCC) after resection. Patients with completely resected metastatic disease (M1 NED) seem to have ...
Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based Combinations [0.03%]
一线免疫检查点抑制剂联合治疗后的二线卡博替尼用于转移性透明细胞肾癌患者的疗效分析
Arshit Narang,Georges Gebrael,Yeonjung Jo et al.
Arshit Narang et al.
Background: Cabozantinib, a tyrosine kinase inhibitor (TKI), is a prevalent second-line (2 L) therapy and was approved for use after progression on TKIs. However, the 1 L treatment setting has changed since the approval o...
Belzutifan versus Everolimus in Advanced Kidney Cancer: A Commentary on LITESPARK-005 Trial from ESMO 2023 [0.03%]
贝芦替范与依维莫司在晚期肾癌中的对比：对ESMO 2023的LITESPARK-005试验的评论
Shuchi Gulati,Primo Nery Lara
Shuchi Gulati
Nicholas R Schindler,David A Braun
Nicholas R Schindler
Immune checkpoint inhibitors (ICIs) have transformed the management of advanced renal cell carcinoma (RCC), but most patients still do not receive a long-term benefit from these therapies, and many experience off-target, immune-related adve...
Erratum to: Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma [0.03%]
卡博替尼剂量增加用于转移性肾细胞癌extended disease control的补充注解 Erratum
Akanksha Sharma,Roy Elias,Alana Christie et al.
Akanksha Sharma et al.
[This corrects the article DOI: 10.3233/KCA-210117.]. © 2023 – The authors. Published by IOS Press.
Published Erratum
Kidney cancer (Clifton, Va.). 2023 Mar 23;7(1):15. DOI:10.3233/KCA-229030 2023
Extended disease control with unconventional cabozantinib dose increase in metastatic renal cell carcinoma [0.03%]
卡博替尼不按常规剂量增加用于转移性肾细胞癌的延长疾病控制作用
Akanksha Sharma,Roy Elias,Alana Christie et al.
Akanksha Sharma et al.
Background: Cabozantinib is among the most potent tyrosine kinase inhibitors (TKIs) FDA-approved for metastatic renal cell carcinoma (mRCC). Effective treatments after progression on cabozantinib salvage therapy are limit...
Immune Checkpoint Inhibitors in the Pre-operative Setting and Impact on the Primary Renal Tumor [0.03%]
新辅助免疫检查点抑制剂治疗对原发肾肿瘤的影响
Shuchi Gulati,Primo Nery Lara
Shuchi Gulati